FCMI
DRNA

Foresite Capital Management IV’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Foresite Capital Management IV’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,000
Closed -$635K – 19
2020
Q2 		$635K Buy
+25,000
New +$539K 0.31% 11

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Foresite Capital Management IV's DRNA Position: Q3 2020 in Review

Foresite Capital Management IV sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 25,000 shares — an estimated $635K sold.

Foresite Capital Management IV first reported a position in DRNA in Q2 2020 and held it in 1 quarter. The position peaked at $635K in Q2 2020. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

  • Foresite Capital Management IV reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Foresite Capital Management IV sold 25,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $635K.
  • Foresite Capital Management IV first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Foresite Capital Management IV's Dicerna Pharmaceuticals, Inc. position peaked at $635K in Q2 2020.
  • 172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Foresite Capital Management IV's 13F filing for Q3 2020, filed 13 Nov 2020.